Review
Biochemistry & Molecular Biology
Stephen D. H. Malnick, Pavel Alin, Marina Somin, Manuela G. Neuman
Summary: Both alcohol-induced liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) involve abnormal fat accumulation in the liver, potentially caused by excessive alcohol consumption and the combination of alcohol consumption and medications. The liver pathology is similar in both conditions, progressing from simple steatosis to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evaluating the medical history of alcohol consumption, laboratory markers, AST/ALT ratio, and features of the metabolic syndrome can help estimate the contribution of alcohol intake and metabolic syndrome to liver steatosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Zelin Tian, Chen Xu, Peijun Yang, Zhibin Lin, Wenlong Wu, Wenjie Zhang, Jian Ding, Rui Ding, Xuan Zhang, Kefeng Dou
Summary: Hepatocellular carcinoma (HCC), caused by viral hepatitis, alcoholic, and non-alcoholic fatty liver disease (NAFLD), is the sixth most common cancer worldwide. Viral hepatitis accounts for 80% of HCC cases globally. NAFLD has become the most common liver disease and major risk factor for HCC in developed countries. This review discusses the specific and similar pathogenesis mechanisms of viral hepatitis-induced HCC and NAFLD-induced HCC, including viral proteins, genetic factors, epigenetic modifications, and abnormal lipid metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Daryl Ramai, Antonio Facciorusso, Erika Vigandt, Bryan Schaf, Waleed Saadedeen, Aditya Chauhan, Sara di Nunzio, Aashni Shah, Luca Giacomelli, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of non-alcoholic fatty liver disease with increasing global incidence, posing an epidemic and public health threat. The disease is associated with major morbidity and mortality, with patients at risk of developing hepatocellular carcinoma. Current evidence suggests a multi-hit model involving various pathways leading to progressive fibrosis and oncogenesis, highlighting the complexity of the disease.
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Medicine, General & Internal
Elizabeth E. Powell, Vincent Wai-Sun Wong, Mary Rinella
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.
Review
Cell Biology
Akihide Kamiya, Kinuyo Ida
Summary: The liver plays a crucial role in maintaining homeostasis and metabolic functions. Non-alcoholic steatohepatitis (NASH) has become a major concern as a cause of liver cirrhosis and cancer. Recent findings suggest that sex-based differences and regulatory mechanisms play a role in NASH-induced liver injury and tumorigenesis.
Article
Immunology
Yan Huang, Qinyi Gan, Rongtao Lai, Weijing Wang, Simin Guo, Zike Sheng, Lu Chen, Qing Guo, Wei Cai, Hui Wang, Gangde Zhao, Zhujun Cao, Qing Xie
Summary: Concurrent non-alcoholic fatty liver disease (NAFLD) is common in chronic hepatitis B (CHB) patients, and non-alcoholic steatohepatitis (NASH) is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. Routine assessment of co-existing NAFLD or NASH is important while coping with chronic HBV infection.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Nutrition & Dietetics
Ludovico Abenavoli, Tiziana Larussa, Alessandro Corea, Anna Caterina Procopio, Luigi Boccuto, Marcello Dallio, Alessandro Federico, Francesco Luzza
Summary: NAFLD, characterized by a wide spectrum of liver disorders, is considered a major public health issue globally. Polyphenols, known for their anti-inflammatory and antioxidant properties, are believed to have potential benefits in preventing and treating NAFLD, though limited human clinical trials are available.
Review
Environmental Sciences
Alexey A. Tinkov, Michael Aschner, Abel Santamaria, Alfred R. Bogdanov, Yousef Tizabi, Miriam B. Virgolini, Ji-Chang Zhou, Anatoly V. Skalny
Summary: The objective of this study was to review existing epidemiological and laboratory findings supporting the role of toxic metal exposure in non-alcoholic fatty liver disease (NAFLD). The existing studies demonstrate a link between exposure to cadmium, lead, arsenic, and mercury and an increased risk of NAFLD, as well as altered liver injury markers. Laboratory studies also show that metal exposure leads to hepatic lipid accumulation and affects metabolic pathways and inflammatory response.
ENVIRONMENTAL RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Andrea Dalbeni, Marco Castelli, Mirko Zoncape, Pietro Minuz, David Sacerdoti
Summary: Non alcoholic steatohepatitis (NASH) is an inflammatory reaction of the liver caused by excessive accumulation of lipids in hepatocytes. It can lead to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is a manifestation of metabolic syndrome, which is associated with subclinical inflammation. Platelets are involved in immune response and activation of stellate cells, and may play a key role in the development of NASH. Antiplatelet drugs have been shown to interrupt this process and improve NASH and metabolic alterations.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Chenhui Ma, Li Han, Zheying Zhu, Cheng Heng Pang, Guoyu Pan
Summary: This review provides an overview of mineral metabolism and its relationship with the pathogenesis of NAFLD. Perturbation of minerals has been found to be associated with the pathological features of NAFLD and potential therapeutic strategies are highlighted. Future directions for targeting mineral metabolism in the treatment of NAFLD are also discussed.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ankica Vujovic, Andjelka M. Isakovic, Sonja Misirlic-Dencic, Jovan Juloski, Milan Mirkovic, Andja Cirkovic, Marina Djelic, Ivana Milosevic
Summary: In this study, the activity of the IL-23/IL-17 axis on the immunohepatotoxicity of chronic liver diseases was investigated. The concentration of plasma IL-23 was associated with NASH, while the concentration of plasma IL-17A was higher and IL-10 was lower in CHC patients compared to controls. Plasma IL-10 was specifically lower in CHC-NSF, while plasma IL-17A was specifically higher in CHC-SF compared to controls. Liver tissue levels of IL-17A and IL-23 were lower in CHC-NSF compared to NASH, regardless of the same liver fibrosis stage. Plasma cytokines, especially IL-6, IL-17A, and IL-23, could be potential markers for differentiating CHC patients from controls.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Endocrinology & Metabolism
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo
Summary: Non-alcoholic fatty liver disease (NAFLD), now renamed as metabolic (dysfunction) associated with fatty liver disease (MAFLD), is a series of diseases characterized by excessive lipid deposition in the liver and often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. While changes in diet and lifestyle are recognized as non-drug treatment strategies, current drug therapies mainly target the pathogenic factors, key links of pathogenesis, and related metabolic disorders of NAFLD. There is still a lack of specific drugs, but treatments based on the enterohepatic axis, targeting gut microbiota, and new metabolism-regulating drugs are emerging.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Immunology
Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
Summary: This study found a significant association between inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD). Increased concentrations of C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1) were significantly associated with increased risks of NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Philippe Rochigneux, Jean-Charles Nault, Francoise Mallet, Anne-Sophie Chretien, Nathalie Barget, Alejandro J. Garcia, Lucie Del Pozo, Valerie Bourcier, Lorraine Blaise, Veronique Grando-Lemaire, Gisele N'Kontchou, Pierre Nahon, Olivier Seror, Marianne Ziol, Nathalie Ganne-Carrie, Daniel Olive
Article
Oncology
Julien Calderaro, Lea Meunier, Cong Trung Nguyen, Marouane Boubaya, Stefano Caruso, Alain Luciani, Giuliana Amaddeo, Helene Regnault, Jean-Charles Nault, Justine Cohen, Frderic Oberti, Sophie Michalak, Mohamed Bouattour, Valerie Vilgrain, Georges-Philippe Pageaux, Jeanne Ramos, Nathalie Barget, Boris Guiu, Valerie Paradis, Christophe Aube, Alexis Laurent, Jean-Michel Pawlotsky, Nathalie Ganne-Carrie, Jessica Zucman-Rossi, Olivier Seror, Marianne Ziol
CLINICAL CANCER RESEARCH
(2019)
Article
Gastroenterology & Hepatology
Jean-Charles Nault, Yoann Martin, Stefano Caruso, Theo Z. Hirsch, Quentin Bayard, Julien Calderaro, Cecile Charpy, Christiane Copie-Bergman, Marianne Ziol, Paulette Bioulac-Sage, Gabrielle Couchy, Jean-Frederic Blanc, Pierre Nahon, Giuliana Amaddeo, Nathalie Ganne-Carrie, Guillaume Morcrette, Laurence Chiche, Christophe Duvoux, Sandrine Faivre, Alexis Laurent, Sandrine Imbeaud, Sandra Rebouissou, Josep M. Llovet, Olivier Seror, Eric Letouze, Jessica Zucman-Rossi
Article
Gastroenterology & Hepatology
Samia Rekik, Manon Allaire, Annie Mumana, Erwan Guyot, Gisele Nkontchou, Veronique Grando, Lorraine Blaise, Marianne Ziol, Pierre Nahon, Nathalie Ganne-Carrie, Olivier Sutter, Olivier Seror, Jean-Charles Nault
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Review
Cell Biology
Kateryna Levada, Alexander Omelyanchik, Valeria Rodionova, Ralf Weiskirchen, Matthias Bartneck
Review
Chemistry, Analytical
Dmitry Murzin, Desmond J. Mapps, Kateryna Levada, Victor Belyaev, Alexander Omelyanchik, Larissa Panina, Valeria Rodionova
Article
Nanoscience & Nanotechnology
Kateryna Levada, Stanislav Pshenichnikov, Alexander Omelyanchik, Valeria Rodionova, Aleksey Nikitin, Alexander Savchenko, Igor Schetinin, Dmitry Zhukov, Maxim Abakumov, Alexander Majouga, Mariia Lunova, Milan Jirsa, Barbora Smolkova, Mariia Uzhytchak, Alexandr Dejneka, Oleg Lunov
Article
Materials Science, Multidisciplinary
A. Omelyanchik, A. Gurevich, S. Pshenichnikov, V Kolesnikova, B. Smolkova, M. Uzhytchak, I Baraban, O. Lunov, K. Levada, L. Panina, V Rodionova
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
(2020)
Article
Chemistry, Multidisciplinary
Elena Kozenkova, Kateryna Levada, Maria V. Efremova, Alexander Omelyanchik, Yulia A. Nalench, Anastasiia S. Garanina, Stanislav Pshenichnikov, Dmitry G. Zhukov, Oleg Lunov, Mariia Lunova, Ivan Kozenkov, Claudia Innocenti, Martin Albino, Maxim A. Abakumov, Claudio Sangregorio, Valeria Rodionova
Article
Materials Science, Multidisciplinary
S. Pshenichnikov, A. Omelyanchik, M. Efremova, M. Lunova, N. Gazatova, V Malashchenko, O. Khaziakhmatova, L. Litvinova, N. Perov, L. Panina, D. Peddis, O. Lunov, V Rodionova, K. Levada
Summary: The study demonstrated the proof-of-concept for antileukemia treatment by inducing reactive oxygen species with magnetic nanoparticles in the presence of moderate-intensity magnetic fields. The enhanced cytotoxic effect on cancer cells while leaving healthy cells unaffected suggests the feasibility of utilizing magnetic nanoparticles controlled by a magnetic field for leukemia treatment.
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
(2021)
Article
Chemistry, Multidisciplinary
Alexander Omelyanchik, Valentina Antipova, Christina Gritsenko, Valeria Kolesnikova, Dmitry Murzin, Yilin Han, Andrei V. Turutin, Ilya V. Kubasov, Alexander M. Kislyuk, Tatiana S. Ilina, Dmitry A. Kiselev, Marina I. Voronova, Mikhail D. Malinkovich, Yuriy N. Parkhomenko, Maxim Silibin, Elena N. Kozlova, Davide Peddis, Kateryna Levada, Liudmila Makarova, Abdulkarim Amirov, Valeria Rodionova
Summary: Polymer-based magnetoelectric composite materials show high potential in various applications such as magnetic field sensors, energy harvesting, and biomedical devices. Current research focuses on increasing the efficiency of magnetoelectric transformation. Strategies such as clustering magnetic nanoparticles and incorporating piezoelectric particles have been proposed to enhance the alpha ME value of the magnetoelectric effect.
Article
Oncology
Karolin Walter, Eva Rodriguez-Aznar, Monica S. Ventura Ferreira, Pierre-Olivier Frappart, Tabea Dittrich, Kanishka Tiwary, Sabine Meessen, Laura Lerma, Nora Daiss, Lucas-Alexander Schulte, Zeynab Najafova, Frank Arnold, Valentyn Usachov, Ninel Azoitei, Mert Erkan, Andre Lechel, Tim H. Brummendorf, Thomas Seufferlein, Alexander Kleger, Enrique Tabares, Cagatay Gunes, Steven A. Johnsen, Fabian Beier, Bruno Sainz Jr, Patrick C. Hermann
Summary: This study demonstrates the critical role of telomerase regulation in maintaining stemness in pancreatic CSCs and examines the effects of telomerase inhibition as a potential treatment option for pancreatic cancer. This may significantly enhance our understanding of PDAC tumor biology and potentially lead to improved treatment for pancreatic cancer patients.
Article
Biochemistry & Molecular Biology
Xiangping Lin, Xinyu Liu, Mohamed N. Triba, Nadia Bouchemal, Zhicheng Liu, Douglas Walker, Tony Palama, Laurence Le Moyec, Marianne Ziol, Nada Helmy, Corinne Vons, Guowang Xu, Carina Prip-Buus, Philippe Savarin
Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with dysregulations in multiple metabolic pathways, including amino acid metabolism, bile acid metabolism, and fatty acid metabolism. These pathway changes are related to altered liver function, mitochondrial dysfunction, and immune system disorders.
Article
Chemistry, Physical
Alexander Omelyanchik, Kateryna Levada, Stanislav Pshenichnikov, Maryam Abdolrahim, Miran Baricic, Anastasiya Kapitunova, Alima Galieva, Stanislav Sukhikh, Lidiia Astakhova, Sergey Antipov, Bruno Fabiano, Davide Peddis, Valeria Rodionova
Article
Engineering, Electrical & Electronic
Anastaiya Gurevich, Anna Beklemisheva, Ekaterina Levada, Valeria Rodionova, Larissa Panina
IEEE MAGNETICS LETTERS
(2020)